A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the dose limiting toxicity and safety of bi-weekly courses of rBBX-01 in patients with resistant solid tumor malignancies.
Four bi-weekly 5 day courses
Janet Rader, MD
Washington University School of Medicine
United States: Food and Drug Administration
|Washington University School of Medicine||Saint Louis, Missouri 63110|